- Conditions
- Advanced Cancer
- Interventions
- LY3475070, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
- Conditions
- Healthy
- Interventions
- TD-5202, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- HER2-positive Carcinoma, HER2-positive Primary Malignancy
- Interventions
- Zr-DFO-pertuzumab PET/CT
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer
- Interventions
- GEN1029 (HexaBody®-DR5/DR5)
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Houston, Texas
- Conditions
- Cognitive Disorders
- Interventions
- SUVN-G3031, Placebo
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Participants
- Interventions
- AZD3974, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- MRT-6160, Placebo
- Drug
- Lead sponsor
- Monte Rosa Therapeutics, Inc
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Healthy Participants
- Interventions
- ID119031166M, Placebo
- Drug
- Lead sponsor
- IlDong Pharmaceutical Co Ltd
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5)
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 38
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- REGN5459
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Indianapolis, Indiana • Ann Arbor, Michigan • Rochester, Minnesota + 4 more
- Conditions
- Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
- Interventions
- TLC-ART
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy Volunteers
- Interventions
- FTX-101, Placebo
- Drug
- Lead sponsor
- Find Therapeutics
- Industry
- Eligibility
- 18 Years to 59 Years · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Coronary Heart Disease
- Interventions
- APL180, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neoplasms
- Interventions
- GSK3368715
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Newport Beach, California • Philadelphia, Pennsylvania + 2 more
- Conditions
- Healthy Adult Immune Responses to Vaccine
- Interventions
- VRC-EBOMAB092-00-AB (MAb114)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Interventions
- ABBV-319
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more
- Conditions
- AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- CER-1236, Cyclophosphamide, Fludarabine, Mesna
- Drug
- Lead sponsor
- CERo Therapeutics Holdings, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Sacramento, California • Denver, Colorado • Nashville, Tennessee + 2 more
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
- Interventions
- MGD009
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Cancer
- Interventions
- GSK923295
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 3
- States / cities
- Duarte, California • Detroit, Michigan • Madison, Wisconsin
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- FWD1509 MsOH
- Drug
- Lead sponsor
- Forward Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Canton, Ohio • Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- BI 1703880, Ezabenlimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more
- Conditions
- Malaria, Healthy Participants
- Interventions
- E1018, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- Interventions
- DS3790a, Combination drug
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York